
EyePoint Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300QE1RU34T50MR69 - ISIN
US30233G2093 (EYPT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. Read full profile
Fundamentals
- Net revenue
€47.80M - Gross margin
93.3% - EBIT
-€137.64M - EBIT margin
-287.9% - Net income
-€125.20M - Net margin
-261.9%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: March 7, 2024 (Q4 2023)